WO2022262859A1 - Anticorps humanisé anti-msln humain et son utilisation - Google Patents
Anticorps humanisé anti-msln humain et son utilisation Download PDFInfo
- Publication number
- WO2022262859A1 WO2022262859A1 PCT/CN2022/099508 CN2022099508W WO2022262859A1 WO 2022262859 A1 WO2022262859 A1 WO 2022262859A1 CN 2022099508 W CN2022099508 W CN 2022099508W WO 2022262859 A1 WO2022262859 A1 WO 2022262859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- binding fragment
- cells
- msln
- Prior art date
Links
- 101150064776 Msln gene Proteins 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 48
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims abstract 13
- 102100025096 Mesothelin Human genes 0.000 claims abstract 13
- 238000009739 binding Methods 0.000 claims description 133
- 230000027455 binding Effects 0.000 claims description 131
- 210000004027 cell Anatomy 0.000 claims description 127
- 108091007433 antigens Proteins 0.000 claims description 102
- 102000036639 antigens Human genes 0.000 claims description 102
- 239000000427 antigen Substances 0.000 claims description 100
- 241000282414 Homo sapiens Species 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 229940121354 immunomodulator Drugs 0.000 claims description 34
- 239000012642 immune effector Substances 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 241000282693 Cercopithecidae Species 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 20
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 19
- 238000010494 dissociation reaction Methods 0.000 claims description 15
- 230000005593 dissociations Effects 0.000 claims description 15
- 241001416177 Vicugna pacos Species 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 210000004602 germ cell Anatomy 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 13
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 claims description 13
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 claims description 8
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 8
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 8
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 6
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000003437 pleural cancer Diseases 0.000 claims description 6
- 239000000700 radioactive tracer Substances 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 108020005243 folate receptor Proteins 0.000 claims description 4
- 102000006815 folate receptor Human genes 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 239000002872 contrast media Substances 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 239000002961 echo contrast media Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 230000005298 paramagnetic effect Effects 0.000 claims description 3
- 239000003504 photosensitizing agent Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 101150075175 Asgr1 gene Proteins 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100024151 Cadherin-16 Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100038449 Claudin-6 Human genes 0.000 claims description 2
- 108090000229 Claudin-6 Proteins 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000762246 Homo sapiens Cadherin-16 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 102100030703 Interleukin-22 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000003515 double negative t cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 abstract description 17
- 108020004707 nucleic acids Proteins 0.000 abstract description 17
- 102000003735 Mesothelin Human genes 0.000 description 125
- 108090000015 Mesothelin Proteins 0.000 description 125
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 238000001514 detection method Methods 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 102220047563 rs587783061 Human genes 0.000 description 11
- 102220225547 rs754043874 Human genes 0.000 description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 102220468361 T cell receptor beta constant 1_H40A_mutation Human genes 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 102220517872 SCO-spondin_W52A_mutation Human genes 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 102220562954 Cytochrome c oxidase subunit 7C, mitochondrial_M39V_mutation Human genes 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102220635881 Prokineticin receptor 1_S40G_mutation Human genes 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000251730 Chondrichthyes Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000013357 binding ELISA Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 210000005033 mesothelial cell Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 102220313179 rs1553259785 Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102220589303 GDNF-inducible zinc finger protein 1_S83A_mutation Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229950001537 amatuximab Drugs 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910001453 nickel ion Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000282852 Lama guanicoe Species 0.000 description 2
- 102220530636 Lysophosphatidic acid receptor 1_L87A_mutation Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000004318 Matrilysin Human genes 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASJSAQIRZKANQN-UHFFFAOYSA-N 2-deoxypentose Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000251204 Chimaeridae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102220595167 GDNF-inducible zinc finger protein 1_T86I_mutation Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- -1 cytosine (C) Chemical compound 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220248504 rs1555565234 Human genes 0.000 description 1
- 102220332750 rs1556614849 Human genes 0.000 description 1
- 102200158856 rs33947112 Human genes 0.000 description 1
- 102220021335 rs80357091 Human genes 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Definitions
- the present disclosure relates to the field of antibodies, in particular to an anti-human MSLN humanized antibody and applications thereof.
- MSLN Mesothelin
- Mesothelin is a differentiation antigen present on normal mesothelial cells, and can be expressed in mesothelial cells of normal pleura, pericardium and peritoneum. Limited expression in normal tissues, but MSLN was found to be expressed in 90% of epithelioid malignant pleural mesothelioma cells, 69% of lung adenocarcinoma cells, 60% of breast cancer cells, 46% of esophageal cancer cells, pancreatic tumor cells and ovarian cancer cells. Therefore, MSLN may become an important target for cancer therapy.
- the MSLN gene is located on chromosome 16p13.3, the full length of the gene is 8kb, the cDNA size is 2138bp, contains an open reading frame of 1884bp, 17 exons, and encodes 628 amino acids.
- the MSLN gene encodes a 71kDa precursor protein.
- the MSLN precursor protein is anchored on the cell membrane by glycophosphatidylinositol (GPI), and can be hydrolyzed by furin into two parts: the N-terminal soluble protein with a molecular weight of 31 kDa, called megakaryocyte enhancer factor ( megakaryocyte-potentiating factor, MPF) and a cell surface glycoprotein with a molecular weight of 40kDa, which is a mature MSLN (Chang K et al., Proc Natl Acad Sci US A.1996; 93(1):136-140; Manzanares et al., Hepatol Commun. 2017;2(2):155-172).
- GPI glycophosphatidylinositol
- mice The biological function of mesothelin has not been fully elucidated.
- researchers have studied mice that knocked out the MSLN gene and found that the mice showed no abnormalities in development, reproduction, and blood cell counts, indicating that it did not affect the normal growth and development of mice. (Bera TK et al., Mol Cell Biol. 2000; 20(8):2902-2906).
- MSLN The abnormal expression of MSLN plays an important role in the proliferation, differentiation, adhesion and drug resistance of tumor cells.
- Overexpression of MSLN can activate multiple signaling pathways of NF- ⁇ B (nuclear factor kappa-light-chain-enhancer of activated B cells), MAPK (mitogen-activated protein kinase) and PI3K (Phosphoinositide 3-kinases), thereby inducing cell apoptosis Promoting cell proliferation, migration and metastasis by inducing the activation and expression of MMP7 (matrix metalloproteinase 7, matrix metalloproteinase-7) and MMP9 (matrix metalloproteinase 9, matrix metalloproteinase-9).
- MSLN can block paclitaxel-induced tumor cell apoptosis and increase cancer cell resistance to drugs by simultaneously activating PI3K/AKT (Protein Kinase B, PKB) and MAPK/ERK (extracellular regulated protein kinases) signaling pathways (Bharadwaj U et al. Mol Cancer. 2011; 10:106; Cheng WF et al. Br J Cancer. 2009; 100(7):1144-1153).
- PI3K/AKT Protein Kinase B, PKB
- MAPK/ERK extracellular regulated protein kinases
- Drug development targeting MSLN includes immunotoxins, vaccines, chimeric monoclonal antibodies, ADCs and CAR-Ts.
- Antibody drugs mainly mediate tumors through antibody neutralization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and binding of antibodies to effector molecules (toxins or inhibitors). Apoptosis or inhibition of tumor cell proliferation, targeted killing of tumor cells.
- the present disclosure provides an anti-human MSLN humanized antibody, a nucleic acid encoding the same, a method for preparing the antibody, a pharmaceutical composition containing the antibody, and related uses of the pharmaceutical composition for treating tumors.
- the present disclosure provides a humanized antibody or antigen-binding fragment that specifically binds human MSLN, the antibody or antigen-binding fragment comprising a heavy chain variable region comprising a complementarity determining Regions CDR1-3 and framework regions FR1-4:
- the CDR1-3 has the sequence shown in SEQ ID NO: 3-5 respectively, the FR1-3 has the FR1-3 derived from the human germline IGHV3-11*05, and the FR4 has the sequence derived from FR4 of IGHJ3*01; or
- the CDR1-3 has the sequence shown in SEQ ID NO: 6-8 respectively, the FR1-3 has the FR1-3 derived from IGHV3-30*01, and the FR4 has the sequence derived from IGHJ3*01 FR4.
- the heavy chain variable region comprises a sequence selected from (1) or (2):
- a sequence having at most 90% identity preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity; or
- the heavy chain variable region has the following characteristics, wherein the position numbers of amino acids are determined by IMGT rules:
- Digit 1 is E or Q; and/or,
- Position 52 is W or L; and/or,
- Position 54 is A or T; and/or,
- the 55th position is Y or T; and/or,
- the 87th bit is L or V
- the heavy chain variable region has the following characteristics, wherein the position numbers of amino acids are determined by IMGT rules:
- the 40th position is G, the 42nd position is Y, the 52nd position is L, the 54th position is A, and the 55th position is T; or,
- the 40th is G
- the 42nd is Y
- the 49th is E
- the 50th is R
- the 52nd is L
- the 54th is A
- the 55th is T
- the 87th is V .
- the heavy chain variable region has the following characteristics, wherein the numbering of amino acid positions is determined by IMGT rules:
- Position 42 is V or Y; and/or,
- the 66th position is Y or K; and/or,
- the 86th position is T or I; and/or,
- the 95th position is R or K; and/or,
- the 96th bit is A or P;
- the heavy chain variable region has the following properties, wherein the amino acid position numbering is determined by the IMGT rules:
- the 40th position is A, the 42nd position is Y and the 52nd position is A; or,
- the equilibrium dissociation constant KD of the antibody or antigen-binding fragment binding to human MSLN is less than 1E-7M, 1E-8M, 1E-9M, 1E-10M, 1E-11M or 1E -12M.
- the antibody or antigen-binding fragment also binds monkey MSLN, preferably, the equilibrium dissociation constant KD of the antibody or antigen-binding fragment binding to monkey MSLN is less than 1E-7M, 1E-8M, 1E -9M, 1E-10M, 1E-11M or 1E-12M.
- the antibody or antigen-binding fragment includes or does not include an antibody heavy chain constant region; optionally, the antibody heavy chain constant region can be selected from human, alpaca, mouse, rat , rabbit or sheep; alternatively, the heavy chain constant region of the antibody may be selected from IgG, IgM, IgA, IgE or IgD, and the IgG may be selected from IgG1, IgG2, IgG3 or IgG4; alternatively, the heavy chain The chain constant region may be selected from an Fc region, a CH3 region, a heavy chain constant region without a CH1 fragment or a complete heavy chain constant region; preferably, the heavy chain constant region is a human Fc region; preferably, the antibody or antigen binding Fragments are heavy chain antibodies.
- the antibody heavy chain constant region can be selected from human, alpaca, mouse, rat , rabbit or sheep; alternatively, the heavy chain constant region of the antibody may be selected from IgG, IgM, IgA, IgE or IgD,
- the antibody or antigen-binding fragment is also coupled with a therapeutic agent or a tracer; preferably, the therapeutic agent is selected from radioisotopes, cytotoxic agents or immunomodulators, the indicated
- the tracer is selected from radiological contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents and photosensitizers; more preferably, the cytotoxic agent is selected from alkaloids, methotrexate methotrexate, doxorubicin, taxanes or toxin compounds.
- the antibody or antigen-binding fragment is also linked with another functional molecule, and the functional molecule can be selected from one or more of the following: signal peptide, protein tag or cytokine; preferably Preferably, the cytokine may be selected from IL-2, IL-6, IL-12, IL-15, IL-21, IFN or TNF-alpha.
- the present disclosure provides a multispecific antibody comprising the antibody or antigen-binding fragment described in the first aspect; preferably, the multispecific antibody further comprises an MSLN-specific binding Antigens other than those described in the first aspect or antibodies or antigen-binding fragments that bind to MSLN epitopes different from those of the antibody or antigen-binding fragment of the first aspect.
- the antigens other than MSLN can be selected from: CD3, preferably CD3 ⁇ ; CD16, preferably CD16A; CD32B; PD-1; PD-2; PD-L1; VEGF; NKG2D; CD19; CD20 ; CD40; CD47; 4-1BB; CD137; EGFR; EGFRvIII; TNF-alpha; CD33; HER2; HER3; HSA; CD5; CD27; EphA2; EpCAM; MUC1; MUC16; CEA; Claudin18.2; Folate receptor; Claudin6 ; WT1; NY-ESO-1; MAGE3; ASGPR1 or CDH16.
- the multispecific antibody can be bispecific, trispecific or tetraspecific, and the multispecific antibody can be bivalent, tetravalent or hexavalent.
- the present disclosure provides a chimeric antigen receptor (CAR), which comprises at least an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain, the The extracellular antigen-binding domain comprises an antibody or antigen-binding fragment optionally selected from the first aspect.
- CAR chimeric antigen receptor
- the present disclosure provides an immune effector cell expressing the chimeric antigen receptor described in the third aspect, or comprising a nucleic acid fragment encoding the chimeric antigen receptor described in the third aspect;
- the immune effector cells are selected from T cells, NK cells (natural killer cell), NKT cells (natural killer T cell), DNT cells (double negative T cell), monocytes, macrophages, dendritic cells or mast cells, the T cells are preferably selected from cytotoxic T cells, regulatory T cells or helper T cells; preferably, the immune effector cells are autoimmune effector cells or allogeneic immune effector cells.
- the present disclosure provides an isolated nucleic acid fragment capable of encoding the antibody or antigen-binding fragment of the first aspect, the multispecific antibody of the second aspect, or the chimeric antigen receptor of the third aspect.
- the present disclosure provides a vector comprising the isolated nucleic acid fragment of the fifth aspect.
- the present disclosure provides a host cell comprising the vector described in the sixth aspect above; preferably, the cell is a prokaryotic cell or a eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast), insect cells or mammalian cells (CHO cell line or 293T cell line).
- the cell is a prokaryotic cell or a eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast), insect cells or mammalian cells (CHO cell line or 293T cell line).
- the present disclosure also provides a method for preparing an antibody or an antigen-binding fragment, or a multispecific antibody, the method comprising culturing the cells described in the seventh aspect above, and isolating the cells under suitable conditions Expressed antibodies or antigen-binding fragments, or isolated multispecific antibodies expressed by said cells.
- the present disclosure also provides a method for preparing immune effector cells, the method comprising introducing the nucleic acid fragment encoding the CAR described in the third aspect into the immune effector cells, optionally, the method further includes Enabling the immune effector cells to express the CAR described in the third aspect.
- the present disclosure also provides a pharmaceutical composition, which comprises the antibody or antigen-binding fragment optionally selected from the first aspect, or the multispecific antibody selected from the second aspect.
- the pharmaceutical composition also includes a pharmaceutically acceptable carrier, diluent or adjuvant; optionally, the pharmaceutical composition also includes an additional antineoplastic agent.
- the present disclosure provides an antibody or antigen-binding fragment optionally selected from the first aspect, or a multispecific antibody optionally selected from the second aspect, or the immune effector described in the fourth aspect
- the present disclosure also provides a method for preventing and/or treating tumors, comprising administering an effective amount of the antibody or antigen-binding fragment optionally selected from the first aspect, or any Selected from the multispecific antibody described in the second aspect, or the immune effector cell described in the fourth aspect, or the nucleic acid fragment described in the fifth aspect, or the carrier described in the sixth aspect; or the eighth and ninth aspects
- the product obtained by the method; or the pharmaceutical composition described in the tenth aspect comprising administering an effective amount of the antibody or antigen-binding fragment optionally selected from the first aspect, or any Selected from the multispecific antibody described in the second aspect, or the immune effector cell described in the fourth aspect, or the nucleic acid fragment described in the fifth aspect, or the carrier described in the sixth aspect.
- the tumor is preferably mesothelioma, lung cancer, breast cancer, esophageal cancer, pancreatic cancer, ovarian cancer or pleural cancer; more preferably epithelioid malignant pleural mesothelioma, lung adenocarcinoma.
- the present disclosure also provides the antibody or antigen-binding fragment described in the first aspect, or the multispecific antibody described in the second aspect, or the immune effector cell described in the fourth aspect, or the antibody described in the fifth aspect.
- the nucleic acid fragment described above, or the carrier described in the sixth aspect, or the product prepared by the method described in the eighth or ninth aspect, or the pharmaceutical composition described in the tenth aspect is used to prevent and/or treat tumors; the tumor Mesothelioma, lung cancer, breast cancer, esophageal cancer, pancreatic cancer, ovarian cancer or pleural cancer are preferred; epithelioid malignant pleural mesothelioma, lung adenocarcinoma are more preferred.
- the present disclosure provides a kit comprising the antibody or antigen-binding fragment optionally selected from the first aspect, or the multispecific antibody optionally selected from the second aspect, or the fourth aspect
- the present disclosure provides a method for inhibiting the proliferation or migration of cells expressing MSLN in vitro, under the condition that a complex can be formed between the antibody or antigen-binding fragment optionally selected from the first aspect and MSLN, The cells are contacted with an antibody or antigen-binding fragment optionally selected from the first aspect.
- the present disclosure provides a method for detecting the expression of MSLN, by allowing the cells to interact with Optionally contacting an antibody or antigen-binding fragment from the first aspect.
- the term “optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where such event or circumstance occurs or does not occur.
- “optionally comprising 1-3 antibody heavy chain variable regions” means that antibody heavy chain variable regions may but need not be present; when present, there may be 1, 2 or 3.
- MSLN refers to Mesothelin (MSLN), which is a differentiation antigen present on normal mesothelial cells and can be expressed in mesothelial cells of normal pleura, pericardium and peritoneum. The expression in normal tissues is limited, but MSLN was found to be highly expressed in epithelioid malignant pleural mesothelioma, lung adenocarcinoma, breast cancer, esophageal cancer, pancreatic tumor and ovarian cancer.
- MSLN includes MSLN proteins of any human and non-human animal species, and specifically includes human MSLN as well as MSLN of non-human mammals.
- the term "specifically binds” means that an antigen-binding molecule (eg, an antibody) specifically binds an antigen and substantially the same antigen with high affinity, typically, but does not bind an unrelated antigen with high affinity. Affinity is usually reflected in an equilibrium dissociation constant (KD), where a lower KD indicates a higher affinity.
- KD equilibrium dissociation constant
- high affinity usually refers to having about 10 -7 M or lower, about 10 -8 M or lower, about 1 ⁇ 10 -9 M or lower, about 1 ⁇ 10 -10 M or lower, KD of 1 ⁇ 10 -11 M or lower or 1 ⁇ 10 -12 M or lower.
- KD KD/Ka, where Kd represents the dissociation rate and Ka represents the on-rate.
- the equilibrium dissociation constant KD can be measured by methods known in the art, such as surface plasmon resonance (eg Biacore) or equilibrium dialysis.
- antibody refers to an immunoglobulin molecule that specifically binds to or is immunoreactive with an antigen of interest, including polyclonal, monoclonal, genetically engineered, and other modified forms of antibodies (including but not Limited to chimeric antibodies, humanized antibodies, fully human antibodies, heteroconjugate antibodies (e.g. bispecific, trispecific and tetraspecific antibodies, diabodies, triabodies and tetrabodies), antibody conjugates) As well as antigen-binding fragments of antibodies (including, for example, Fab', F(ab')2, Fab, Fv, rIgG and scFv fragments).
- immunoglobulins can be divided into five classes, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are respectively the ⁇ chain and the delta chain , ⁇ chain, ⁇ chain and ⁇ chain.
- IgM, IgD, IgG, IgA, and IgE immunoglobulins
- their corresponding heavy chains are respectively the ⁇ chain and the delta chain , ⁇ chain, ⁇ chain and ⁇ chain.
- the same class of Ig can be divided into different subclasses according to the amino acid composition of its hinge region and the number and position of heavy chain disulfide bonds.
- IgG can be divided into IgG1, IgG2, IgG3, IgG4, and IgA can be divided into IgA1 and IgA.
- Light chains are classified as either kappa chains or lambda chains by difference in the constant region.
- Each of the five Ig classes can have either a kappa chain or a lambda chain.
- Antibody herein also includes antibodies that do not comprise light chains, for example, antibodies produced from Camelus dromedarius, Camelus bactrianus, Lama glama, Lama guanicoe and alpaca (The heavy-chain antibodies (HCAbs) produced by Vicugna pacos) and the new immunoglobulin antigen receptor (Ig new antigen receptor, IgNAR) found in cartilaginous fishes such as sharks.
- HCAbs heavy-chain antibodies
- Ig new antigen receptor Ig new antigen receptor
- an antibody fragment refers to one or more antibody fragments that retain the ability to specifically bind a target antigen.
- the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
- An antibody fragment may be a Fab, F(ab') 2 , scFv, SMIP, diabody, triabody, affibody, Nanobody, aptamer or domain antibody.
- binding fragments encompassing the term "antigen-binding fragment" of an antibody include, but are not limited to: (i) Fd fragments consisting of VH and CH1 domains; (ii) dAb fragments or VHH consisting of VH domains; (iii) Isolated complementarity determining regions (CDRs); (iv) heavy chain antibody fragments consisting of VHH and CH2, CH3; and (v) combinations of two or more isolated CDRs, which may optionally be synthesized from Joint connection.
- CDRs complementarity determining regions
- These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments are screened for use in the same manner as whole antibodies.
- Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or in some embodiments by chemical peptide synthesis procedures known in the art.
- heavy chain antibody refers to an antibody that lacks the light chains of conventional antibodies.
- the term specifically includes, but is not limited to, homodimeric antibodies comprising a VH antigen binding domain and CH2 and CH3 constant domains in the absence of a CH1 domain.
- the term “nanobody” refers to the natural heavy chain antibody that lacks the light chain in camels, and its variable region can be cloned to obtain a single domain antibody consisting of only the variable region of the heavy chain, also known as VHH (Variable domain of heavy chain of heavy chain antibody), which is the smallest functional antigen-binding fragment.
- VHH Very domain of heavy chain of heavy chain antibody
- VHH domain and “nanobody” and “single domain antibody” (single domain antibody, sdAb) have the same meaning and are used interchangeably, and refer to the variable domain of a cloned heavy chain antibody. region, to construct a single domain antibody consisting of only one heavy chain variable region, which is the smallest fully functional antigen-binding fragment. Usually, after obtaining the heavy chain antibody that naturally lacks the light chain and heavy chain constant region 1 (CH1), the variable region of the heavy chain of the antibody is cloned to construct a single domain antibody consisting of only one heavy chain variable region.
- CH1 light chain and heavy chain constant region 1
- the term "monoclonal antibody” refers to an antibody derived from a single clone (including any eukaryotic, prokaryotic, or phage clone), without limitation by the method by which the antibody was produced.
- multispecific means having at least two antigen-binding sites, each of which is associated with a different epitope of the same antigen or with a different epitope of a different antigen. Binding of different epitopes.
- terms such as “bispecific”, “trispecific”, “tetraspecific” and the like refer to the number of different targets or epitopes to which an antibody/antigen binding molecule can bind.
- valence refers to the presence of a defined number of binding sites in an antibody/antigen binding molecule. Accordingly, the terms “monovalent”, “bivalent”, “tetravalent” and “hexavalent” denote one binding site, two binding sites, four binding sites and six binding sites in an antibody/antigen binding molecule, respectively. point of existence.
- an “antibody” herein may be derived from any animal, including but not limited to humans and non-human animals selected from primates, mammals, rodents and vertebrates, such as camelids, llamas , guanaco, alpaca, sheep, rabbit, mouse, rat or cartilaginous fishes (eg sharks).
- chimeric antibody refers to an antibody that has variable sequences derived from immunoglobulins of one source organism (such as rat, mouse, rabbit, or alpaca) as well as those derived from a different organism.
- the constant region of an (eg, human) immunoglobulin e.g., Morrison, 1985, Science 229(4719):1202-7; Oi et al., 1986, Bio Techniques 4:214-221; Gillies et al., 1985 J Immunol Methods 125:191-202; incorporated by reference above and into this article.
- humanized antibody refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase sequence homology with a human antibody.
- all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (for example, variable region FR and/or constant region) is derived from a human Immunoglobulin (receptor antibody).
- Humanized antibodies usually retain or partially retain the expected properties of the donor antibody, including but not limited to, antigen specificity, affinity, reactivity, ability to enhance immune cell activity, ability to enhance immune response, etc.
- the term "fully human antibody” refers to antibodies having variable regions in which both the FRs and CDRs are derived from human germline immunoglobulin sequences. Furthermore, if the antibody comprises a constant region, the constant region also is derived from human germline immunoglobulin sequences. Fully human antibodies herein may include amino acid residues not encoded by human germline immunoglobulin sequences (eg, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, “fully human antibodies” herein do not include antibodies in which CDR sequences derived from the germline of another mammalian species (eg, mouse) have been grafted onto human framework sequences.
- another mammalian species eg, mouse
- variable region refers to the region of an antibody heavy or light chain that is involved in making the antibody bind to an antigen
- “heavy chain variable region” is used interchangeably with “VH” and “HCVR”
- “light chain “Variable region” and “VL” and “LCVR” are used interchangeably.
- the variable domains (VH and VL, respectively) of the heavy and light chains of native antibodies generally have similar structures, with each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). See, eg, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., p.91 (2007).
- VH or VL domain may be sufficient to confer antigen binding specificity.
- complementarity determining region and “CDR” are used interchangeably and generally refer to the hypervariable region (HVR) of the variable region of the heavy chain (VH) or the variable region of the light chain (VL), which is due to the In terms of spatial structure, it can form a precise complementarity with the antigenic epitope, so it is also called complementarity determining region.
- the heavy chain variable region CDR can be abbreviated as HCDR
- LCDR light chain variable region
- frame region or "FR region” are used interchangeably and refer to those amino acid residues in an antibody heavy chain variable region or light chain variable region other than the CDRs.
- FR region usually consists of 4 FR regions and 3 CDR regions in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (see Kabat et al., Sequences of Protein of Immunological Interest, National Institute of Health, Bethesda, Md. 1987; incorporated herein by reference).
- CDR1-VH, CDR2-VH and CDR3-VH refer to the first CDR, the second CDR and the third CDR of the heavy chain variable region (VH), respectively, and these three CDRs constitute the CDR combination (VHCDR combination) of the chain (or its variable region);
- CDR1-VL, CDR2-VL and CDR3-VL refer to the first CDR, second CDR and second CDR of the light chain variable region (VL), respectively
- IMGT numbering system generally refers to a numbering system based on The international ImMunoGeneTics information system (IMGT) initiated by Lefranc et al., see Lefranc et al., Dev.Comparat . Immunol. 27:55-77, 2003.
- IMGT ImMunoGeneTics information system
- the term “heavy chain constant region” refers to the carboxy-terminal portion of the heavy chain of an antibody that is not directly involved in binding the antibody to antigen, but exhibits effector functions, such as interaction with Fc receptors, which are relative to The variable domains of antibodies have more conserved amino acid sequences.
- the "heavy chain constant region” at least includes: CH1 domain, hinge region, CH2 domain, CH3 domain, or variants or fragments thereof.
- “Heavy chain constant region” includes "full-length heavy chain constant region” and “heavy chain constant region fragment”, the former has a structure substantially similar to that of a natural antibody constant region, while the latter only includes “full-length heavy chain constant region” part".
- a typical "full-length antibody heavy chain constant region” consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain In the case of an antibody, it does not include a CH1 domain.
- typical "heavy chain constant region fragments" can be selected from Fc or CH3 domains.
- the term "light chain constant region” refers to the carboxy-terminal part of the antibody light chain, which is not directly involved in the binding of the antibody to the antigen, and the light chain constant region may be selected from a constant kappa domain or a constant lambda domain.
- Fc region is used to define the C-terminal region of an antibody heavy chain that contains at least a portion of the constant region.
- the term includes native sequence Fc regions and variant Fc regions.
- a human IgG heavy chain Fc region can extend from Cys226 or Pro230 to the carboxyl terminus of the heavy chain.
- antibodies produced by host cells may undergo post-translational cleavage whereby one or more, especially one or two amino acids are excised from the C-terminus of the heavy chain.
- an antibody produced by a host cell by expression of a specific nucleic acid molecule encoding a full-length heavy chain may include the full-length heavy chain, or it may include cleavage variants of the full-length heavy chain.
- the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbering according to the Kabat EU index). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present.
- the IgG Fc region includes IgG CH2 and IgG CH3 domains, optionally, on this basis, it can also include a complete or partial hinge region, but does not include a CH1 domain.
- the "CH2 domain" of a human IgG Fc region generally extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, the carbohydrate chain is attached to the CH2 domain.
- the CH2 domain herein may be a native sequence CH2 domain or a variant CH2 domain.
- a "CH3 domain" comprises the stretch of residues in the Fc region that is C-terminal to the CH2 domain (ie, from the amino acid residue at about position 341 to the amino acid residue at about position 447 of IgG).
- the CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g. having a "knob” ("knob”, knob) introduced in one of its chains and a correspondingly introduced “cavity” in the other chain thereof (CH3 domain of a "hole”; see US Patent No. 5,821,333, expressly incorporated herein by reference).
- a variant CH3 domain e.g. having a "knob” ("knob”, knob) introduced in one of its chains and a correspondingly introduced “cavity” in the other chain thereof (CH3 domain of a "hole”; see US Patent No. 5,821,333, expressly incorporated herein by reference).
- such variant CH3 domains can be used to facilitate heterodimerization of two non-identical antibody heavy chains.
- the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, such as Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Described in Institutes of Health, Bethesda, MD, 1991.
- germline or “germline sequence” refers to the sequence of sequences encoded by the unrearranged (unrearranged) immunoglobulin V, D and/or J regions, or portions thereof, present in the genomic DNA of an organism. amino acid sequence. Germline represents the basic genetic information transmitted from parent to sibling prior to any functional rearrangement in the coding sequence of the gene. Non-germline gene products are produced in the case of antibody homologous recombination of individual germline genes encoding variable (V), diversity (D, heavy chain-specific) and joining genes (J); VDJ for heavy chain , and VJ for the light chain.
- V variable
- D diversity
- J heavy chain-specific
- J joining genes
- the term "derived from a specified sequence” refers to the origin of the sequence.
- the derivative sequence derived from a specific starting sequence has an amino acid sequence substantially identical to the starting sequence or a part of the same amino acid sequence.
- the "derived sequence” and the “starting sequence” have at least 80%, 85%, 90% or 95% identity.
- conservative amino acid generally refers to amino acids that belong to the same class or have similar characteristics (eg, charge, side chain size, hydrophobicity, hydrophilicity, backbone conformation, and rigidity).
- conservative substitutions for each other are examples of amino acids that are considered conservative substitutions for each other:
- percent (%) sequence identity and “percent (%) identity” are used interchangeably and refer to the sequence after aligning sequences and introducing gaps (if necessary) to achieve the maximum percent sequence identity ( For example, for optimal alignment, gaps may be introduced in one or both of the candidate and reference sequences, and non-homologous sequences may be ignored for comparison purposes), after the amino acid (or nucleotide) of the candidate sequence ) residues are identical to the amino acid (or nucleotide) residues of the reference sequence.
- alignment can be achieved in a number of ways well known to those skilled in the art, for example, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAi) software.
- a reference sequence aligned for comparison with a candidate sequence may show that the candidate sequence exhibits a 50% to 100% sequence identity.
- the length of a candidate sequence aligned for comparison purposes may be, for example, at least 30% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) of the length of the reference sequence .
- chimeric antigen receptor refers to an artificial cell surface receptor engineered to be expressed on immune effector cells and specifically bind an antigen comprising at least (1) an extracellular antigen binding domain , such as the variable heavy or light chain of an antibody, (2) the transmembrane domain that anchors the CAR into immune effector cells, and (3) the intracellular signaling domain.
- CARs are able to redirect T cells and other immune effector cells to a target of choice, such as cancer cells, in a non-MHC-restricted manner using an extracellular antigen-binding domain.
- antibody conjugate refers to a couple/conjugate formed by chemically bonding an antibody molecule to another molecule either directly or through a linker.
- ADC antibody-drug conjugate
- the "another molecule” may be selected from a therapeutic agent or a tracer; preferably, the therapeutic agent is selected from a radioisotope, a cytotoxic agent or an immunomodulator, and the tracer is selected from a radiological contrast agent, Paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents and photosensitizers; more preferably, the cytotoxic agents are selected from the group consisting of alkaloids, methotrexate, anthracyclines (doxorubicin) or taxanes (taxanes).
- nucleic acid includes any compound and/or substance comprising a polymer of nucleotides.
- Each nucleotide consists of a base, especially a purine or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose) and phosphate groups.
- cytosine C
- G guanine
- A adenine
- T thymine
- U uracil
- nucleic acid molecules are described by a sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule.
- the sequence of bases is usually expressed 5' to 3'.
- nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including for example complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), especially messenger RNA (mRNA), synthetic forms of DNA or RNA, and synthetic forms of DNA or RNA comprising both Mixed polymers of one or more of these molecules.
- Nucleic acid molecules can be linear or circular.
- nucleic acid molecule includes both sense and antisense strands, as well as single- and double-stranded forms.
- nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides.
- Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of antibodies of the present disclosure in vitro and/or in vivo, eg, in a host or patient.
- DNA eg cDNA
- RNA eg mRNA
- Such DNA (eg cDNA) or RNA (eg mRNA) vectors may be unmodified or modified.
- mRNA can be chemically modified to enhance the stability of the RNA vector and/or the expression of the encoded molecule, so that the mRNA can be injected into a subject to generate antibodies in vivo (see e.g.
- An "isolated" nucleic acid herein refers to a nucleic acid molecule that has been separated from components of its natural environment.
- An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but which is present extrachromosomally or at a chromosomal location other than its natural chromosomal location.
- vector includes nucleic acid vectors, such as DNA vectors (eg, plasmids), RNA vectors, viruses or other suitable replicons (eg, viral vectors).
- DNA vectors eg, plasmids
- RNA vectors eg, viruses or other suitable replicons
- viral vectors eg, viral vectors.
- a variety of vectors have been developed for the delivery of polynucleotides encoding foreign proteins into prokaryotic or eukaryotic cells.
- Expression vectors of the present disclosure contain polynucleotide sequences together with additional sequence elements, eg, for expressing proteins and/or integrating these polynucleotide sequences into the genome of mammalian cells.
- vectors that can be used to express the antibodies and antibody fragments of the present disclosure include plasmids that contain regulatory sequences, such as promoter and enhancer regions, that direct transcription of the gene.
- Other useful vectors for expressing antibodies and antibody fragments contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of mRNA resulting from transcription of the genes. These sequence elements include, for example, 5' and 3' untranslated regions, internal ribosomal entry sites (IRES), and polyadenylation signal sites to direct the efficient transcription of genes carried on the expression vector.
- Expression vectors of the present disclosure may also contain polynucleotides encoding markers for selection of cells containing such vectors. Examples of suitable markers include genes encoding resistance to antibiotics such as ampicillin, chloramphenicol, kanamycin or nourthricin.
- the step of transforming host cells with recombinant DNA described in this disclosure can be performed by conventional techniques well known to those skilled in the art.
- the obtained transformants can be cultured by conventional methods and express the polypeptides encoded by the genes of the present disclosure.
- the medium used in the culture can be selected from various conventional media according to the host cells used.
- the host cells are cultured under conditions suitable for the growth of the host cells.
- the term "pharmaceutical composition” refers to a preparation that is in a form that permits the biological activity of the active ingredients contained therein to be effective and that does not contain substances that are unsuitable for the subject to which the pharmaceutical composition is administered. Additional ingredients of acceptable toxicity.
- the terms "subject”, “subject” and “patient” refer to an organism receiving treatment for a particular disease or condition, such as cancer or an infectious disease, as described herein.
- subjects and patients include mammals, such as humans, primates, pigs, goats, rabbits, hamsters, cats, dogs, Guinea pigs, members of the bovid family (such as domestic cattle, bison, buffalo, elk, and yaks), cattle, sheep, horses, and bison.
- treatment refers to surgical or therapeutic treatment, the purpose of which is to prevent, slow down (reduce) an undesired physiological change or pathology in the subject being treated, such as a cell proliferative disorder (such as cancer or infectious disease).
- a cell proliferative disorder such as cancer or infectious disease.
- Beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms, diminished extent of disease, stable disease state (i.e., not worsening), delay or slowing of disease progression, amelioration or palliation of disease state, and remission (whether partial response or complete response), whether detectable or undetectable.
- Those in need of treatment include those already with the condition or disease as well as those prone to have the condition or disease or those in which the condition or disease is to be prevented.
- slow down lessen, weaken, moderate, alleviate, etc., the meaning of eliminate, disappear, not occur, etc. is also included.
- the term "effective amount” refers to an amount of a therapeutic agent effective to prevent or alleviate a disease condition or the progression of the disease when administered alone or in combination with another therapeutic agent to a cell, tissue or subject. "Effective amount” also refers to an amount of a compound sufficient to relieve symptoms, eg, treat, cure, prevent or alleviate the associated medical condition, or to increase the rate of treatment, cure, prevent or alleviate such condition.
- a therapeutically effective dose refers to that ingredient alone.
- a therapeutically effective dose refers to the combined amounts of the active ingredients that produce a therapeutic effect, whether administered in combination, sequentially or simultaneously.
- cancer refers to or describes the physiological condition in mammals typically characterized by unregulated cell growth. Both benign and malignant cancers are included in this definition.
- tumor or “neoplastic” refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- cancer and “tumor” are not mutually exclusive when referred to herein.
- FIG. 1 Amino acid numbering (IMGT) of huNB149-95-graft and huNB149-70-graft;
- Fig. 3. detects the binding activity of human MSLN-FL-his protein and anti-MSLN antibody for ELISA
- Figure 6A is the FACS result of detecting the expression level of HEK293T-monkey MSLN cells with NB149 antiserum;
- Figure 6B is the FACS detection of the binding reaction of the control antibody to HEK293T-monkey MSLN cells
- 7A-7C are ELISA detection of the binding reaction of humanized antibody and human MSLN full-length protein
- 8A to 8C are FACS detection of the binding reaction of the humanized antibody to HEK293T-human MSLN cells
- 9A-9C are FACS detection of the binding reaction of the humanized antibody to OVCAR3 cells.
- Figures 10A to 10C are ELISA detection of the binding reaction of the humanized antibody to the full-length monkey MSLN protein
- 11A-11C are FACS detection of the binding reaction of humanized antibody to HEK293T-monkey MSLN cells.
- Alpaca (Alpaca, code: NB149) was immunized with human MSLN (Glu296-Gly580)-Fc protein (purchased from Acro, product number: MSN-H5253). Alpaca peripheral blood was collected, PBMCs were isolated, total RNA was extracted, and reverse transcribed into cDNA. The nucleic acid fragment encoding the variable region of the single domain antibody was amplified by nested PCR, cloned into a phage display vector, and electrotransformed into Escherichia coli electroporation competent cell TG1. A phage display library of single domain antibody against human MSLN was constructed and tested. After multiple rounds of panning, positive clones of anti-human MSLN single domain antibody were screened from the library. The VHH sequence information and CDRs information of the positive clones were obtained by sequencing and sequence analysis, see Table 1 for details.
- the VHH sequences of NB149-95 and NB149-70 were recombined into the human IgG1 Fc expression vector to obtain recombinant plasmids.
- the construction of the plasmid and the expression and purification of the antibody were completed by Taizhou Baiying Biotechnology Co., Ltd., and the purified chimeric antibodies NB149-95 VHH-hFc and NB149-70 VHH-hFc were obtained.
- the human IgG1 Fc sequence information comes from WO1997000319A2, as follows:
- NB149-95 VHH-hFc and NB149-70 VHH-hFc bind to human MSLN protein and cells expressing human MSLN protein, and have good specific binding activity to cells expressing monkey MSLN protein.
- VHH-hFc and His-tagged human MSLN protein were further detected by Biacore technology, and the specific detection methods included: using a Protein A chip ( GE Healthcare; 29-127-558) captures anti-human MSLN VHH-hFc.
- Sample and running buffer was HBS-EP+(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20) (GE Healthcare; BR-1006-69).
- the flow-through cell was set to 25°C.
- the sample block was set to 16°C. Both were pretreated with running buffer.
- IGHV3-11*05 and IGHJ3*01 were selected as the humanization of alpaca antibody NB149-95
- IGHV3-30*01 and IGHJ3*01 were selected as the humanized heavy chain template for alpaca-derived antibody NB149-70.
- the CDRs of alpaca antibodies were grafted into the FRs of their human templates to form variable region sequences in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
- the key amino acids in the FR region sequence of the humanized antibody were back-mutated to the corresponding amino acids of the alpaca antibody to ensure the original affinity.
- the humanized antibody VHs designed by the above methods are shown in Table 3 and Table 4, respectively, and the specific sequence information is shown in Table 5.
- the numbering of amino acid residues and the CDR region of the antibody in this example are determined and annotated by the IMGT numbering system. For example, the amino acid numbering of huNB149-95-graft and huNB149-70-graft is shown in FIG. 1 .
- S40G means that the 40th position is mutated from S to G, and so on for the rest, where the number of amino acid residues is determined by IMGT.
- H40A means that the 40th position is mutated from H to A, and the rest can be deduced by analogy, where the number of amino acid residues is determined by IMGT.
- the underlined area is the CDR region, and the rest is the framework region, and the border with characters indicates the position of the mutation.
- the MSLN humanized antibody is expressed in the form of VHH-his. Antibody expression and purification was undertaken by Taizhou Baiying Biotechnology Co., Ltd. The purified humanized antibody was tested for protein concentration, purity, and endotoxin (Lonza kit), and the results are shown in Table 6. The results showed that, except for huNB149-95-H4, the purity of which was lower than 90%, the endotoxin concentration Within 5.0EU/mg, the purity of other antibodies was >98%, and the endotoxin concentration was within 1.0EU/mg.
- Both the positive control antibody and the negative control antibody were constructed by Taizhou Baiying Biotechnology Co., Ltd. and the production and purification of antibodies were completed.
- NB149-95 SEQ ID NO: 1 to construct an antibody in the form of VHH-his, named NB149-95-his.
- the sequence of Amatuximab comes from the patent US20140127237A1, which is in the form of hIgG1 and named Tab142.
- the YP223 sequence comes from the patent US20150252118A1, which is constructed as a rabbit IgG1 antibody and named Tab020.
- Negative control The isotype negative control of the MSLN humanized antibody is an irrelevant antibody m971 that does not bind to the MSLN protein.
- the sequences of the heavy chain variable region and light chain variable region are from the patent US 8591889B, constructed as VH-(G4S)3-VL -his form, named Tab084.
- the isotype negative control of Amatuximab is the antibody against Hen Egg Lysozyme chicken egg lysozyme (purchased from Baiying, product number: B117901), named hIgG1.
- MSLN protein has three IgG-like domains extracellularly, of which Region1 (R1) is located at the farthest membrane end, and Region3 (R3) is located at the proximal membrane end.
- Region1 Region1
- R3 Region3
- the nucleotide sequence containing the amino acid sequence Glu296-Gly580 (MSLN-FL) of the extracellular region encoding human MSLN protein (NCBI: AAH09272.1) was cloned into the pTT5 vector (completed by General Biosystems (Anhui) Co., Ltd.) and followed by The established standard molecular biology method prepares the plasmid, and the specific method is referred to Sambrook, J., Fritsch, EF, and Maniatis, T. (1989).
- HEK293E cells purchased from Suzhou Yiyan Biotechnology Co., Ltd.
- PI Protein Engineering Company
- FreeStyle TM 293 Thermofisher scientific, catalog number: 12338018
- the culture supernatant was loaded onto a nickel ion affinity chromatography column HisTrap TM Excel (GE Healthcare, product number: GE17-3712-06), and an ultraviolet (UV) detector was used to monitor changes in ultraviolet absorbance (A280nm).
- UV ultraviolet
- the tagged human MSLN protein was dialyzed with PBS phosphate buffer (pH 7.4) at 4°C overnight.
- the dialyzed protein was sterile-filtered at 0.22 microns and stored at -80°C to obtain purified human MSLN extracellular region protein.
- the target bands of samples detected by SDS-PAGE reducing gel and non-reducing gel are shown in Figure 2.
- Human MSLN-FL-his protein has binding activity with the control antibody, which is consistent with the binding characteristics of Tab142 (Amatuximab) reported in the literature. It shows that the human MSLN protein with binding activity has been prepared.
- the nucleotide sequence encoding the full-length amino acid sequence of human MSLN was cloned into pcDNA3.1 vector and a plasmid was prepared.
- HEK293T cell line purchased from ATCC
- plasmid 3000Transfection Kit
- use rabbit anti-human MSLN antibody (Tab020) and goat anti-rabbit IgG Fab antibody cell signaling, product number: 4414S
- were used to sort positive monoclonal cells on a flow cytometer FACSAria II purchasedd from BD Biosciences to a 96-well plate, and placed at 37°C.
- the nucleotide sequence encoding the full-length amino acid sequence of monkey MSLN (NCBI: XP_028696439.1) was cloned into the pcDNA3.1 vector and a plasmid was prepared.
- HEK293T cell line (purchased from ATCC) was transfected with plasmid ( 3000 Transfection Kit, purchased from Invitrogen, product number: L3000-015), and selectively cultured in DMEM/F12 medium containing 5 ⁇ g/mL puromycin and 10% (w/w) fetal bovine serum for 2 weeks, with limited Subcloning was carried out in a 96-well culture plate by the dilution method, and cultured at 37° C., 5% (v/v) CO 2 .
- Figure 6B shows that the positive control antibody Tab142 has cross-binding activity with HEK293T-monkey-MSLN (see Example 4.1 for the specific method), which again verifies that HEK293T-monkey-MSLN can be used in subsequent experiments.
- human MSLN protein purchased from Acro, product number: MSN-H5253
- PBS fetal bovine serum
- 96-well ELISA 96-well ELISA
- the plate was sealed with a plastic film and incubated overnight at 4°C.
- the plate was washed twice with PBST, and the blocking solution [PBS+2% (w/w) BSA] was added to block at room temperature for 2 hours. Pour off the blocking solution, wash the plate twice with PBST, and add the test antibody or control antibody with an initial concentration of 100nM and a 1:10 gradient dilution at 50 ⁇ l/well.
- FACS buffer PBS+2% fetal calf serum
- Example 5.2 The preparation of detection cells and antibody to be tested and the detection method refer to Example 5.2.
- the results are shown in Figures 9A-9C and Tables 14-15, huNB149-95-H6, huNB149-95-H7, huNB149-95-H8 and huNB149-70-H6 had a better correlation with OVCAR3 endogenous cells expressing human MSLN protein. binding activity, and no binding activity to A431 cells that do not express human MSLN protein. The binding activities of the remaining humanized antibodies were weakened to varying degrees, or even completely lost.
- the monkey MSLN full-length protein (purchased from Biointron, catalog number: 20210308A031) was diluted with PBS to a final concentration of 2 ⁇ g/mL, and ELISA was performed according to the method in Example 5.1 Detection and data analysis. The results are shown in Figures 10A to 10C and Table 16-17. Humanized huNB149-95-H6, huNB149-95-H7, huNB149-95-H8, huNB149-70-H6 and huNB149-70-H8 have effects on monkey MSLN protein The binding activity is well retained.
- HEK293T-monkey MSLN cells and HEK293T cells were collected, and FACS detection and data analysis were performed according to the method in Example 5.2.
- the analysis results are shown in Figures 11A-11C and Tables 18-19, wherein Tab084 is a negative control; NB149-95-his is a positive control.
- the results showed that humanized antibodies huNB149-95-H6, huNB149-95-H7, huNB149-95-H8, huNB149-70-H6 and huNB149-70-H8 retained good binding to recombinant cells expressing monkey MSLN protein active.
- the BIAcore 8K instrument was used to detect the binding strength of the antibody to the antigen by the anti-human antibody capture method.
- the Anti-Human IgG antibody was immobilized on the CM5 chip (Cytiva; 29-1496-03) by amino coupling method, and the HBS -EP+pH7.4 (10mM HEPES, 150mM NaCl, 3mM EDTA, 0.05% surfactant P20) (Cytiva; BR-1006-69) as the mobile phase, after mixing NHS and EDC, activate the chip for about 600 seconds, and use 10mM acetic acid Dilute Anti-Human IgG antibody to 15 ⁇ g/mL with sodium pH 5.0, inject for 420 seconds, and finally block the remaining activation sites with ethanolamine.
- the affinity of the antibody to the antigen was determined by a multi-cycle kinetic method.
- human MSLN-Fc protein purchased from Acro, catalog number: MSN-H5253
- MSN-H5253 human MSLN-Fc protein
- 3M MgCl 2 where the mobile phase is HBS-EP+pH7.4, the flow rate is 30 ⁇ L/min, the regeneration time is 30 seconds, and the detection temperature 25°C.
- the surface plasmon resonance (SPR) method was used to determine the affinity between the MSLN humanized antibody and the monkey MSLN protein (purchased from Biointron, product number: 20210308A031), and the experimental method was referred to Example 7.1.
- the binding rate (Kd), dissociation rate (Ka) and binding affinity (KD) of the MSLN humanized antibody to the monkey MSLN protein are shown in Table 21.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un anticorps humanisé anti-MSLN humain et son utilisation. En particulier, la présente invention concerne un anticorps humanisé anti-MSLN humain, un acide nucléique codant pour celui-ci, un procédé de préparation d'un anticorps, une composition pharmaceutique contenant l'anticorps, et l'utilisation associée de la composition pharmaceutique pour traiter une tumeur.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280037440.7A CN117412991A (zh) | 2021-06-18 | 2022-06-17 | 抗人msln人源化抗体及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110681168.3 | 2021-06-18 | ||
CN202110681168 | 2021-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022262859A1 true WO2022262859A1 (fr) | 2022-12-22 |
Family
ID=84526890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/099508 WO2022262859A1 (fr) | 2021-06-18 | 2022-06-17 | Anticorps humanisé anti-msln humain et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117412991A (fr) |
WO (1) | WO2022262859A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023199069A1 (fr) * | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Récepteur antigénique chimérique qui se lie à la mésothéline |
US11981745B2 (en) | 2021-10-06 | 2024-05-14 | Link Immunotherapeutics, Inc. | Anti-mesothelin antigen-binding molecules and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004121A1 (en) * | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
CN107840891A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗msln抗体及其应用 |
CN109705219A (zh) * | 2019-01-08 | 2019-05-03 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
WO2019223579A1 (fr) * | 2018-05-21 | 2019-11-28 | 荣昌生物制药(烟台)有限公司 | Anticorps anti-mésothéline et conjugué anticorps-médicament associé |
WO2020011970A1 (fr) * | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Anticorps anti-mésothéline |
CN110698562A (zh) * | 2019-10-31 | 2020-01-17 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
CN111349165A (zh) * | 2020-05-25 | 2020-06-30 | 南京蓝盾生物科技有限公司 | 抗人msln单克隆抗体及其应用 |
-
2022
- 2022-06-17 CN CN202280037440.7A patent/CN117412991A/zh active Pending
- 2022-06-17 WO PCT/CN2022/099508 patent/WO2022262859A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004121A1 (en) * | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
CN107840891A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗msln抗体及其应用 |
WO2019223579A1 (fr) * | 2018-05-21 | 2019-11-28 | 荣昌生物制药(烟台)有限公司 | Anticorps anti-mésothéline et conjugué anticorps-médicament associé |
WO2020011970A1 (fr) * | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Anticorps anti-mésothéline |
CN109705219A (zh) * | 2019-01-08 | 2019-05-03 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
CN110698562A (zh) * | 2019-10-31 | 2020-01-17 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
CN111349165A (zh) * | 2020-05-25 | 2020-06-30 | 南京蓝盾生物科技有限公司 | 抗人msln单克隆抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
HO M, FENG M, FISHER R J, RADER C, PASTAN I.: "A novel high-affinity human monoclonal antibody to mesothelin.", INTERNATIONAL JOURNAL OF CANCER, vol. 128, no. 9, 1 May 2011 (2011-05-01), US , pages 2020 - 2030, XP002715757, ISSN: 0020-7136, DOI: 10.1002/ijc.25557 * |
JIANG JING;XIN WEI;LI SHENJUN;GAO DONG: "Advances in Research on Mesothelin Targeting Therapeutic Biologics", PROGRESS IN PHARMACEUTICAL SCIENCES, no. 12, 25 December 2019 (2019-12-25), pages 922 - 934, XP093015904 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11981745B2 (en) | 2021-10-06 | 2024-05-14 | Link Immunotherapeutics, Inc. | Anti-mesothelin antigen-binding molecules and uses thereof |
WO2023199069A1 (fr) * | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Récepteur antigénique chimérique qui se lie à la mésothéline |
Also Published As
Publication number | Publication date |
---|---|
CN117412991A (zh) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6571527B2 (ja) | 二重特異性抗体 | |
WO2022262859A1 (fr) | Anticorps humanisé anti-msln humain et son utilisation | |
EP3928790A1 (fr) | Fragment de liaison à l'antigène cd3 et application de celui-ci | |
CN111744013A (zh) | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 | |
WO2022121928A1 (fr) | Nanocorps anti-egfr et utilisation associée | |
WO2022121941A1 (fr) | Anticorps msln antihumain et application associée | |
WO2022242703A1 (fr) | Anticorps anti-msln et son application | |
WO2023125888A1 (fr) | Anticorps gprc5d et son utilisation | |
WO2022135536A1 (fr) | Anticorps cd3 humanisé et son utilisation | |
WO2022127844A1 (fr) | Anticorps cd5 et son utilisation | |
WO2022171100A1 (fr) | Anticorps gpc3 humanisé et son utilisation | |
WO2022105811A1 (fr) | Anticorps cd19 humanisé et son utilisation | |
WO2022127889A1 (fr) | Anticorps her2 et son utilisation | |
WO2022121969A1 (fr) | Anticorps gpc3 et son utilisation | |
WO2021143914A1 (fr) | Anticorps anti-ox40, son procédé de production et son application | |
WO2023098846A1 (fr) | Nanocorps anti-bcma et son utilisation | |
WO2023274183A1 (fr) | Anticorps anti-cd16 et son utilisation | |
WO2022206900A1 (fr) | Nanocorps d'albumine sérique humaine (hsa) et leurs utilisations | |
WO2023280297A1 (fr) | Anticorps cd19 et son application | |
WO2022171113A1 (fr) | Anticorps cd33 humain et son utilisation | |
WO2023186100A1 (fr) | Anticorps anti-ror1 et son utilisation | |
WO2022152282A1 (fr) | Anticorps monoclonaux anti-cd22 humain et leur utilisation | |
WO2022117032A1 (fr) | Nanoanticorps anti-cd22 et son utilisation | |
WO2023011431A1 (fr) | Anticorps anti-cd16 et son utilisation | |
WO2023104138A1 (fr) | Anticorps anti-bcma et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22824331 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280037440.7 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22824331 Country of ref document: EP Kind code of ref document: A1 |